Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy. However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in HCC and overcomes chemotherapy resistance in other settings. We studied the efficacy of combining the anti-EGFR antibody cetuxi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sanoff, Hanna K., Bernard, Stephen, Goldberg, Richard M., Morse, Michael A., Garcia, Reynaldo, Woods, Lynna, Moore, Dominic T., O'Neil, Bert H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: International Society of Gastrointestinal Oncology 2011
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3201640/
https://ncbi.nlm.nih.gov/pubmed/22043322
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge